August 10, 2021
Read for 2 minutes
ADD SUBJECT TO EMAIL ALERTS
Receive an email when new articles are published on
Please enter your email address to receive an email when new articles are published on . “data-action = subscribe> Subscribe
We could not process your request. Please try again later. If this problem persists, please contact [email protected].
Back to Healio
A phase 2 study sponsored and funded by the National Institute of Allergy and Infectious Diseases of the NIH will examine the antibody response of a third dose of a COVID-19 messenger RNA vaccine in kidney transplant recipients.
As with other vaccinations, there is evidence that patients who have undergone a transplant may not respond optimally to COVID-19 vaccination due to the immunosuppressive therapy they must take to prevent organ rejection, the NIH said in a press release fixed.
A newly announced study will evaluate the effectiveness of a third dose of the COVID-19 mRNA vaccine in kidney transplant recipients. Source: NIAID
The new study will seek to determine whether a third dose of a COVID-19 mRNA vaccine will overcome this problem and whether there are features that distinguish transplant recipients who might benefit from a third dose from those who take a different approach, need the NIH., said.
The pilot study, called COVID Protection After Transplant (CPAT), is being conducted at Johns Hopkins University and will include up to 200 people aged 18 years or older who received a kidney transplant 1 year or more prior to admission and more recently had no organ rejection or changes in immunosuppression. All participants had little or no detectable antibody response to two doses of an mRNA vaccine.
To mark the announcement of the study, we have compiled a list of six current stories about COVID-19 booster doses and immunocompromised patients.
Questions and Answers: Reduced Effectiveness of COVID-19 Vaccines in Transplant Recipients
A study of COVID-19 vaccine reactions in kidney transplant recipients in Israel suggested that they could be at high risk for COVID-19 even after vaccination. We spoke to a member of the editorial board of Infectious Disease News Peter Chin-Hong, MD, Professor of Medicine and Director of the Transplant Infectious Disease Program at the University of California, San Francisco, on the impact of COVID-19 on transplant programs and the effectiveness of COVID-19 vaccines in transplant recipients. Continue reading.
Organ Transplant Recipients “Should Not Accept Immunity To COVID-19 Vaccine”
Only 54% of solid organ transplant recipients showed evidence of antibody development after receiving a COVID-19 vaccine, according to data in two research letters published in JAMA. Continue reading.
According to study results, a booster dose could make transplant recipients less susceptible to COVID-19
Johns Hopkins researchers found that a booster dose could make transplant recipients less susceptible to infection. In a study published in the Annals of Internal Medicine, they reported that a third dose of the COVID-19 vaccine increased antibody levels in a third of patients with negative levels and all patients with low positive antibody levels after two doses. Continue reading.
The COVID-19 vaccine response varies widely in immunocompromised patients
According to an interim analysis published in medRxiv, about 84% of patients with autoimmune diseases develop antibodies from the COVID-19 vaccine, compared with 98.1% of healthy healthcare workers. The results showed great heterogeneity in the COVID-19 vaccine response in immunocompromised patients, with only one in five lung transplant participants developing an antibody response and a nearly complete response in patients with well-controlled HIV, the researchers wrote. Continue reading.
There are “limited data” on COVID-19 boosters in immunocompromised patients
On July 12, the Israeli Ministry of Health began offering a third dose of the Pfizer mRNA vaccine to severely immunocompromised adults, which could usher in a similar booster approach in elderly and vulnerable populations in other parts of the world, including the United States. Continue reading.
CDC, FDA say booster doses are not required as a Pfizer eye approval
Pfizer and BioNTech announced positive initial results from an ongoing study evaluating a booster dose of their COVID-19 vaccine and planned to file the data with the FDA soon. However, federal health officials said a COVID-19 vaccine booster program was not yet needed and fully vaccinated people would be protected from serious illness from all SARS-CoV-2 viruses, including variants. Continue reading.
ADD SUBJECT TO EMAIL ALERTS
Receive an email when new articles are published on
Please enter your email address to receive an email when new articles are published on . “data-action = subscribe> Subscribe
We could not process your request. Please try again later. If this problem persists, please contact [email protected].
Back to Healio
